Harvard Bioscience (HBIO) AI Stock Analysis

• Market Cap: $25.04M
• Dividend Yield: N/A
• Average Volume (3M): 56.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: -10.60%
• EPS Growth: -271.93%
• Country: US
• Employees: 330
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 4,471,989
• 10 Day Avg. Volume: 68,604
• 30 Day Avg. Volume: 56,592
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 5.29
• Enterprise Value/Market Cap: 2.42
• Enterprise Value/Revenue: 0.70
• Enterprise Value/Gross Profit: 1.32
• Enterprise Value/Ebitda: 11.42
• 1Y Price Target: $6.00
• Price Target Upside: 1400.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1
• Revenue Forecast (FY): $92.60M

• Rating: 50 Neutral
• Price Target: $5.50 ▲(1275.00% Upside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

HBIO’s score is held back primarily by weak financial performance (sharp TTM revenue decline and large losses), with only partial offset from positive near-term cash generation. The latest earnings call provides a constructive but modest recovery outlook (limited growth and EBITDA improvement guidance), while technical indicators remain soft and valuation is difficult to support due to ongoing losses and no dividend yield.

Positive Factors

Cash generation

Consistent positive trailing‑12‑month operating and free cash flow despite GAAP losses indicates the business still converts sales into cash. That cash generation supports working capital, funds restructuring and NPI investment, and provides a durable buffer while the company executes its turnaround.

Refinancing & lower debt service

Refinancing that extends maturities and cuts annual debt service materially lowers near‑term liquidity pressure and interest burden. The $3M cash savings improve financial flexibility, reduce refinancing risk and free cash for product development and margin expansion over the medium term.

Manufacturing consolidation & NPI focus

Centralizing manufacturing and prioritizing high‑margin translational NPIs and recurring consumables should improve operating leverage and gross margins. Structural savings and SKU rationalization enhance unit economics, while expanding consumables/recurring revenue (~55% target) increases predictable, higher‑margin revenue over time.

Negative Factors

Large GAAP losses

A large goodwill impairment and resulting substantial GAAP loss reflect prior overvaluation and erode equity cushions. Persistent GAAP losses impair return metrics, constrain reinvestment capacity, and signal that operational recovery must be sustained to restore shareholder equity and long‑term profitability.

Revenue decline & regional softness

An ongoing revenue decline and weakness across core regions reduces scale needed to absorb fixed costs and slows margin recovery. Persistent top‑line pressure undermines the cadence of recurring consumables and services revenue and makes multi‑period margin improvement dependent on execution and NPI adoption.

Funding & tariff sensitivity

Concentration of orders tied to government funding and exposure to trade/tariff shifts creates structural revenue volatility. Dependence on NIH timing and export/import policy means forecasting and capacity planning remain uncertain, raising execution risk for a company seeking steady recovery.

Harvard Bioscience Business Overview & Revenue Model

Company Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

How the Company Makes Money

HBIO primarily makes money by selling life science research tools and instrumentation to laboratories and research organizations. Key revenue streams include: (1) instrument and equipment sales—revenue from the sale of lab devices and systems used in research and preclinical workflows; (2) consumables and accessories—recurring revenue from items that are replaced or replenished during routine use (e.g., single-use components and lab accessories that support installed instruments); (3) services—revenue from support offerings tied to its installed base, such as maintenance, repair, calibration, training, and other customer support services; and (4) software/related components—revenue from software or integrated components that support data acquisition, control, and analysis for certain systems. Sales are generated through a mix of direct commercial channels and third-party distributors (where applicable), and results are influenced by research funding levels, capital equipment purchasing cycles, and demand for consumables and services from the installed base. Specific material partnerships or customer concentration details: null.

Harvard Bioscience Financial Statement Overview

Summary

Financial profile is weak: TTM revenue declined to about $86.6M and profitability deteriorated sharply (operating margin ~-57%, net margin ~-62%). Positives include positive TTM operating cash flow (~$6.5M) and free cash flow (~$5.1M), but cash generation has been volatile historically and the most recent balance-sheet inputs show inconsistencies, reducing confidence in the latest leverage snapshot.

Income Statement

Profitability has deteriorated sharply in TTM (Trailing-Twelve-Months): revenue fell to ~$86.6M (about -94% growth shown in the data) and losses widened materially, with net margin around -62% and operating margin around -57%. While gross margin remains relatively solid (~56%), the cost structure is not absorbing the revenue decline, and earnings quality has weakened versus 2023–2024 when losses were far smaller and operating results were closer to break-even.

Balance Sheet

Historical leverage looks moderate (debt-to-equity roughly ~0.6–0.75 in 2020–2024), but returns on equity have been consistently negative, reflecting an inability to earn an adequate return on the capital base. The TTM (Trailing-Twelve-Months) balance-sheet inputs appear internally inconsistent (e.g., zero debt and zero equity alongside a high debt-to-equity figure), which limits confidence in the most recent leverage snapshot; based on the cleaner annual history, the balance sheet is not overly levered but remains pressured by ongoing losses.

Cash Flow

Cash generation is a relative bright spot: TTM (Trailing-Twelve-Months) operating cash flow is positive (~$6.5M) and free cash flow is also positive (~$5.1M), implying the business is still producing cash despite large reported net losses. However, free cash flow declined versus the prior period (negative growth shown), and cash flow has been volatile historically (negative free cash flow in 2021–2022 and 2024), creating higher execution risk and less consistency than higher-quality cash compounders.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	86.55M	94.14M	112.25M	113.33M	118.90M
Gross Profit	45.88M	54.77M	66.07M	60.82M	67.65M
EBITDA	5.32M	-1.47M	8.03M	944.00K	9.02M
Net Income	-56.70M	-12.40M	-3.42M	-9.52M	-288.00K
Balance Sheet
Total Assets	80.07M	126.64M	137.37M	145.36M	162.34M
Cash, Cash Equivalents and Short-Term Investments	8.61M	4.11M	4.28M	4.51M	7.82M
Total Debt	44.28M	44.49M	42.77M	54.24M	56.96M
Total Liabilities	66.34M	63.30M	64.29M	73.14M	78.94M
Stockholders Equity	13.73M	63.34M	73.07M	72.22M	83.40M
Cash Flow
Free Cash Flow	5.62M	-1.82M	11.72M	-438.00K	-83.00K
Operating Cash Flow	6.73M	1.44M	14.03M	1.15M	1.26M
Investing Cash Flow	-1.86M	-1.34M	-1.80M	-1.59M	-1.34M
Financing Cash Flow	-1.29M	-131.00K	-12.13M	-2.84M	-252.00K

Harvard Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HBIO, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 5.48, below the 50-day MA of 5.63, and below the 200-day MA of 5.38, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 40.05 is Neutral, neither overbought nor oversold. The STOCH value of 45.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HBIO.

Harvard Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	54 Neutral	$37.06M	-1.12	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXGL	51 Neutral	$8.35M	-7.45	-55.33%	―	73.38%	34.87%
HBIO	50 Neutral	$25.04M	-0.52	-388.56%	―	-10.60%	-271.93%
RVP	48 Neutral	$20.82M	16.98	-8.13%	―	-0.95%	58.17%
MLSS	42 Neutral	$22.96M	-8.10	-164.78%	―	0.59%	-39.76%

Harvard Bioscience Corporate Events

Harvard Bioscience Highlights CFO Appointment and Strategic Repositioning

In its latest investor presentation dated March 2026, Harvard Bioscience outlines recent strategic and financial actions, including the appointment of John Duke as CEO effective July 2025 and Mark Frost as permanent CFO in March 2026, as well as an expanded board with several new directors joining through late 2025. The company refinanced its debt to extend maturities to 2029, reduced annual debt service with $3 million in yearly cash savings, secured a $7.5 million BroadOak convertible note investment, and initiated a phased closure of its Holliston, Mass., plant, which is expected to improve adjusted EBITDA by about $3 million in 2027 and $4 million from 2028, while sharpening its focus on translational science products announced in February 2026.

Management emphasizes that Harvard Bioscience is repositioning itself as a leading provider of translational science tools by integrating in vivo telemetry with in vitro organoid platforms, advancing new product innovation in telemetry, electrophysiology, and organoids, and expanding higher-margin recurring revenue from software, consumables, and services. With JD Edwards ERP consolidation completed in 2024, a streamlined global manufacturing footprint, and plans to move its headquarters to Minneapolis in the first quarter of 2027, the company aims to unlock operating leverage and capitalize on regulatory support for New Approach Methodologies, strengthening its competitive advantages, pricing power, and long-term growth prospects for stakeholders.

The most recent analyst rating on (HBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Harvard Bioscience Updates Executive Contracts and Finance Leadership

On March 6, 2026, Harvard Bioscience, Inc. amended and restated the employment agreement for Chief Executive Officer John Duke, extending his term to July 16, 2027 with automatic two‑year renewals, raising his annual base salary to $515,000 and providing a special $100,000 cash bonus tied to the successful refinancing of the company’s credit facility. The revised deal also increases his variable compensation opportunity through annual cash incentives of up to 80% of base salary, a 2026 target equity grant of 75,000 restricted stock units following a 1‑for‑10 reverse stock split effective March 13, 2026, and enhanced severance and vesting protections upon certain termination or change‑in‑control events.

The board simultaneously strengthened its finance leadership by appointing Mark Frost as Chief Financial Officer and Treasurer effective March 6, 2026, following his service as interim finance chief since April 10, 2025. Frost’s new employment agreement runs to April 10, 2027 with automatic two‑year extensions, sets a $375,000 base salary with up to 60% annual cash incentive eligibility, targets a 2026 equity grant of 30,000 restricted stock units post‑split, and provides structured severance and benefits upon qualifying termination events, signaling the company’s focus on retaining senior executives during a period of capital structure and governance adjustments.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Harvard Bioscience Approves Reverse Stock Split to Regain Compliance

Harvard Bioscience held a special shareholder meeting on March 6, 2026, at which investors approved a reverse stock split and a potential meeting adjournment to secure that vote. Following the approval, the board set a 1-for-10 split ratio and filed an amended charter in Delaware, reducing the number of outstanding shares from about 44.7 million to roughly 4.47 million while keeping authorized shares unchanged.

The reverse split will take legal effect at 4:30 p.m. Eastern on March 13, 2026, and the stock is expected to begin trading on a split-adjusted basis on Nasdaq under the existing HBIO ticker, but with a new CUSIP, on March 16, 2026. The move is intended to lift the company’s per-share trading price to regain compliance with Nasdaq’s minimum bid requirement, and will include cash in lieu of fractional shares and proportional adjustments to options, warrants and other convertible securities, affecting how both existing shareholders and equity holders are positioned going forward.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Harvard Bioscience Announces Major Global Manufacturing Consolidation

On January 23, 2026, Harvard Bioscience’s board approved “Project Viking,” a strategic consolidation of manufacturing aimed at improving efficiency and supporting long-term growth, centered on closing the Holliston, Massachusetts facility and shifting U.S. production to the company’s Minneapolis, Minnesota hub, while relocating certain operations to centers of excellence in Germany, Sweden and the UK. The Holliston plant will remain operational through 2026, with the phased consolidation expected to be substantially complete by the first quarter of 2027, generating an estimated $3 million in cost savings in 2027 and about $4 million in annual savings thereafter, driven by reduced overhead, SKU rationalization, better asset utilization and workforce reconfiguration, although the company expects to incur $3.4 million to $4.4 million in pre-tax restructuring charges and transition-related operating expenses through the first half of 2027 as it seeks to streamline its footprint, improve execution and enhance long-term value for customers and shareholders.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Harvard Bioscience Lowers Quorum Requirement for Shareholders

On January 19, 2026, Harvard Bioscience’s Board of Directors approved an amendment to the company’s Amended and Restated By-laws that lowers the quorum requirement for stockholder meetings from a majority to one-third of the shares entitled to vote. The change, which took effect immediately upon Board approval, is expected to make it easier for the company to achieve quorum at shareholder meetings, potentially streamlining corporate governance processes and facilitating timely decision-making for investors and management.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Harvard Bioscience Issues Strategic Investor Update Presentation

In January 2026, Harvard Bioscience released an investor update presentation outlining its business strategy, operational progress and financial outlook, emphasizing its leading positions in high-demand preclinical telemetry tools, organoid research platforms and translational medicine tools. The company highlighted solid year-to-date performance, including third-quarter 2025 revenue of $20.6 million at the high end of guidance, gross margin expansion to 58.4% and higher adjusted EBITDA driven by lower operating expenses, and set 2025 priorities around maintaining financial discipline and positive cash generation, accelerating adoption of core growth platforms and strengthening its capital structure via debt refinancing, positioning itself for improved profitability and long-term growth for stakeholders.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.78 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.